All these data suggest the role of PGK1 as an oncogene in SMAD4-negative PDA patients and its presence could predict the metastatic fate of tumors, proposing this glycolytic enzyme as a potential therapeutic target. This evidence concerns the gene SMAD4 and Patent ductus arteriosus.